FDA's Botanical Drug RFI (FDA-2026-N-9550): What Canadian NHP and Cannabis Companies Should Say Before 3 November

On 4 September 2026, the United States Food and Drug Administration opened a public docket asking industry, researchers and clinicians a direct question: what is holding back the development of botanical drug products, and how can it be fixed? The request for information (RFI), published at 91 FR 56887 under Docket No. FDA-2026-N-9550, is open for comment until 11:59 pm Eastern Time on 3 November 2026. Late comments will not be considered.

For Canadian companies, this is more than a US housekeeping notice. Many natural health product (NHP) and cannabis firms already grow, extract and test plant material to a high standard. The RFI signals that the FDA is rethinking how those same materials can become approved prescription medicines in the United States. If you have ever wondered whether your botanical could be more than a supplement south of the border, this is the moment to understand the pathway and, if it fits, to comment. This article explains what a botanical drug product is, what the RFI asks, and how the US and Canadian systems differ.

Executive Summary

The FDA defines a botanical drug product (BDP) as a drug that includes or may be derived from plant materials, algae, macroscopic fungi, or combinations, intended to diagnose, cure, mitigate, treat or prevent disease in humans. Only four botanical products have ever been approved as prescription drugs in the United States, three under new drug applications and one under a biologics license application. The RFI seeks input on the barriers to developing more of them, including clinical trial design, production quality and consistency, and study designs for complex mixtures. For Canadian NHP and cannabis companies, the central lesson is that a US botanical drug is a full FDA-regulated drug, not a supplement, so the evidence bar, the quality expectations and the regulatory route are far higher than a Health Canada NHP licence. Firms considering this path should map their existing quality and evidence data onto FDA expectations now, and can submit a comment to the docket before 3 November 2026.

What Is a Botanical Drug Product?

A botanical drug product is a medicine made from botanical sources and intended to treat disease. In the RFI, the FDA uses the terms botanicals, botanical drug products and BDPs to mean drug products that include or may be derived from plant materials, algae, macroscopic fungi, or combinations, and that are intended for the diagnosis, cure, mitigation, treatment or prevention of disease in humans. BDPs can take many forms, including teas, powders, tablets, capsules, tinctures, topicals and injections. The defining feature is the intended use: a therapeutic claim against a disease makes the product a drug under the US Federal Food, Drug, and Cosmetic Act.

The FDA published its guidance for industry Botanical Drug Development on 29 December 2016. That document, first issued in draft in 2000, finalized in 2004, revised in 2015 and finalized again in 2016, sets out recommendations on characterization, quality control, clinical investigation and regulatory considerations for BDPs. To date, four botanical products have reached the US market as prescription drugs: three under new drug applications, containing sinecatechins, crofelemer and birch triterpenes, and one under a biologics license application, containing anacaulase-bcdb. Separately, botanical ingredients such as psyllium and witch hazel can be marketed under certain over-the-counter monographs.

What the RFI Asks

The RFI is a request for information, not a proposed rule, so it does not change any requirement today. It asks stakeholders to describe their experience and to suggest solutions. Why it matters: the answers will shape whether the FDA revises its guidance or creates new tools for botanical development, which directly affects any Canadian firm planning a US drug submission. What to do: read the questions, decide whether your experience is relevant, and consider submitting a comment. The questions fall into three groups.

Question group	What the FDA is asking about
Research and development experience	Challenges in botanical research and development programs, differences between healthy-volunteer and patient studies, use of existing FDA resources, and systems that help gather the information the FD&C Act requires
General challenges	Scientific and economic barriers to BDP development, and the difference between developing minimally purified or whole-plant products versus highly purified or isolate products
General opportunities	Innovative approaches to accelerate development, ways to streamline without affecting safety, efficacy or quality, useful guidance updates, standards development outside FDA, study designs for complex mixtures, and use of well-established use and real-world evidence

The RFI follows a botanical drug development roundtable at which external participants identified several opportunities: incorporating real-world evidence into fit-for-purpose development programs, identifying and applying appropriate quality frameworks to address batch-to-batch variability and ensure reproducibility, and increasing education and outreach to align understanding across the development ecosystem. Comments go to the docket at regulations.gov, and the FDA contact for the notice is the Center for Drug Evaluation and Research at botanicaldrugproducts@fda.hhs.gov.

Why This Matters to Canadian NHP and Cannabis Firms

In Canada, most plant-based products reach the market as natural health products under the Natural Health Products Regulations, or as cannabis products under the Cannabis Act. These are not drugs in the FDA sense. A US botanical drug, by contrast, is a full prescription medicine that requires an investigational new drug application, clinical trials, and a new drug or biologics license application. Why it matters: the same plant extract can be a licensed NHP in Canada and an unapproved new drug in the United States. What to do: before you invest, understand that moving from an NHP to a US botanical drug is a change of regulatory universe, not a relabelling exercise. How it affects compliance: your evidence, your quality systems and your manufacturing controls all step up to drug-grade expectations.

Classification is the first hurdle, and Canadian firms already know how much rides on it. The same care that decides whether a substance is a raw material or a finished NHP, or whether an ingredient like a peptide is a drug or a natural health product, applies when you weigh an NHP licence against a US botanical drug submission. The cannabis sector is squarely in scope, because the RFI covers plant-derived medicines and even macroscopic fungi, which brings certain psychedelic and mushroom-derived candidates into the conversation.

Botanical Drug vs Natural Health Product: Two Different Systems

The clearest way to see the gap is side by side. The table below compares a Canadian NHP with a US botanical drug at a high level. It is a simplification, and every product is different, but it shows why the decision deserves a formal assessment rather than a hunch.

Feature	Canadian NHP (NHPR)	US botanical drug (FD&C Act)
Regulator	Health Canada, Natural and Non-prescription Health Products Directorate	FDA, Center for Drug Evaluation and Research
Product status	Natural health product	Prescription drug (or OTC monograph in limited cases)
Pre-market pathway	Product licence (NPN) and site licence	Investigational new drug application, then NDA or BLA
Evidence standard	Safety and efficacy supported by acceptable evidence for the claim	Substantial evidence of effectiveness from adequate and well-controlled trials
Quality framework	NHP GMP (GUI-0158) and good agricultural and collection practices	Drug GMP plus botanical-specific quality controls for consistency
Typical claims	Structure-function and limited therapeutic claims	Disease treatment claims

The Quality Problem: Batch-to-Batch Variability

The single hardest technical problem in botanical drug development is consistency. A plant is not a synthesized molecule. Growing conditions, harvest timing, drying, extraction and storage all shift the chemical profile, so two batches of the same botanical can differ. The RFI names batch-to-batch variability and reproducibility as a core challenge and asks how appropriate quality frameworks can address it. Why it matters: the FDA cannot approve a drug it cannot rely on to be the same each time. What to do: build identity, potency and impurity control into the supply chain from the field forward. How it affects compliance: this is exactly where good agricultural and collection practices (GACP) and good manufacturing practices (GMP) earn their keep.

Canadian cannabis and NHP firms that have pursued export markets already understand GACP and GMP discipline, as our EU-GMP and GACP certification roadmap explains. The same controls that prevent adulteration and keep identity honest, a subject we cover in our NHP adulteration playbook, are the foundation of a credible botanical drug quality package. A firm that can demonstrate a validated, reproducible supply chain has a head start on the FDA's central concern.

How to Decide and How to Comment

There are two decisions in front of Canadian firms right now: whether to comment on the RFI, and whether the US botanical drug pathway is worth pursuing at all. Both benefit from the same groundwork. Here is a practical sequence.

Confirm the intended use. If you will make a disease treatment claim in the United States, you are in drug territory, and an NHP or supplement route will not cover you.
Inventory your evidence. Compare what you hold for your Canadian NHP file against the substantial-evidence standard for a US drug, and identify the clinical gap.
Audit your quality data. Assess whether your GACP and GMP records demonstrate the batch-to-batch consistency the FDA flags as the core barrier.
Decide on a comment. If you have real development experience or a concrete solution, a well-argued comment to Docket FDA-2026-N-9550 can help shape future guidance. Do not include confidential business information in a public comment.
Meet the deadline. The docket closes at 11:59 pm Eastern Time on 3 November 2026, and late comments will not be considered.
Model the investment. An IND and pivotal trials are a multi-year commitment. Decide whether the US drug market justifies it, or whether an NHP or supplement route better fits your product and budget.

Compliance Checklist

Work through this checklist before deciding whether the US botanical drug pathway fits your product.

Define the intended use and confirm whether a disease claim places the product in the US drug category.
Map your Canadian NHP or cannabis evidence against the US substantial-evidence standard.
Document identity, potency and impurity specifications for the botanical raw material and finished product.
Verify GACP controls from cultivation and collection through to extraction.
Confirm GMP controls and a validated process that can demonstrate batch-to-batch consistency.
Review the FDA 2016 Botanical Drug Development guidance and the RFI questions relevant to your product.
Decide whether to submit a comment to Docket FDA-2026-N-9550 before 3 November 2026, with no confidential information in the public version.
Build a realistic timeline and budget for an IND and clinical program before committing.

Common Mistakes

Assuming a Canadian NHP licence carries weight in the US drug system. It does not. A botanical drug is a full FDA drug requiring an IND and an NDA or BLA.
Underestimating the quality burden. Batch-to-batch variability is the barrier the FDA names first, and weak GACP or GMP records will stop a program early.
Treating the RFI as a rule. It is a request for information and changes no requirement today, but the responses may shape future guidance.
Putting confidential business information in a public comment. Anything filed to the public docket may be posted at regulations.gov unchanged.
Missing the deadline. Comments must arrive by 11:59 pm Eastern Time on 3 November 2026; late submissions will not be considered.

Frequently Asked Questions

What is a botanical drug product under the FDA?

It is a drug product that includes or may be derived from plant materials, algae, macroscopic fungi, or combinations, and is intended to diagnose, cure, mitigate, treat or prevent disease in humans. It can be a tea, powder, tablet, capsule, tincture, topical or injection. The therapeutic intent makes it a drug under the US Federal Food, Drug, and Cosmetic Act.

How many botanical drugs has the FDA approved?

Four botanical products have been approved as US prescription drugs: three under new drug applications, containing sinecatechins, crofelemer and birch triterpenes, and one under a biologics license application, containing anacaulase-bcdb. Some botanical ingredients, such as psyllium and witch hazel, can also be marketed under over-the-counter monographs.

Can a Canadian natural health product be approved as a US botanical drug?

Not directly. A Canadian NHP licence does not transfer to the US drug system. To sell the same botanical as a US prescription drug, you would need an investigational new drug application, clinical trials, and an approved new drug or biologics license application. The plant material and some quality data may support the effort, but the regulatory route is separate and far more demanding.

When does the RFI comment period close?

The comment period closes at 11:59 pm Eastern Time on 3 November 2026. Comments are submitted to Docket No. FDA-2026-N-9550 at regulations.gov. Late, untimely filed comments will not be considered.

Does the RFI apply to cannabis or psychedelic products?

The RFI defines botanicals to include plant materials, algae and macroscopic fungi, so plant-derived cannabis medicines and certain mushroom-derived candidates can fall within its scope. It does not change the separate controlled-substance rules that also apply to those products in Canada and the United States.

What is the biggest quality challenge for botanical drugs?

Batch-to-batch variability. Because botanicals are complex natural mixtures, their composition can change with growing conditions, harvest and processing. The FDA flags reproducibility as a core barrier, which makes strong GACP and GMP controls, identity testing and process validation essential to a credible submission.

How MFLRC Can Help

Choosing between a Health Canada NHP pathway and a US FDA botanical drug pathway is a strategic decision with long consequences. MFLRC provides senior-led regulatory affairs, licensing and import and export advice to help you make it. We assess your product against both systems, map your existing evidence and quality data onto FDA expectations, and set out a realistic route and timeline before you commit budget.

On the quality side, our quality assurance and quality control services build the identity, potency and impurity specifications and the GACP and GMP controls that answer the FDA's batch-to-batch concern. Firms already exporting to the United States will know the discipline from our guide to 21 CFR Part 111 for Canadian NHP exporters. We also help draft evidence-based comments to the FDA docket where a comment supports your commercial goals.

If your near-term priority is a strong Canadian NHP foundation, our coverage of the new NHP Quality Guide will help you get the quality base right first, which is the same base a future botanical drug program will build on.

Weighing a US botanical drug pathway or an RFI comment? MFLRC can assess your product against both the Canadian NHP and US drug systems and map the route. Book a consultation.

Book a Consultation

Conclusion

The botanical drug RFI is a signal that the FDA wants more plant-based medicines to reach patients, and that it knows the current path is hard. For Canadian NHP and cannabis firms, the opportunity is real but the bar is high: a US botanical drug is a full FDA drug, and quality consistency is the hurdle to clear. Companies that already run disciplined GACP and GMP operations are best placed to respond, whether by commenting before 3 November 2026 or by starting a serious pathway assessment. As with any cross-border plan, understanding the full range of US routes, including the generic ANDA and 505(b)(2) options, lets you choose the path that fits your product and your budget.